Proactive Investors - Run By Investors For Investors

UPDATE: Tissue Regenix produces impressive results in leg ulcer trial

Shares in Tissue Regenix were lifted more than 12% today as its replacement skin continued to generate impressive results in a UK trial to treat chronic leg ulcers.
UPDATE: Tissue Regenix produces impressive results in leg ulcer trial

---Adds share price and quotes from managing director---

Shares in Tissue Regenix (LON:TRX) were lifted more than 12% today as its replacement skin continued to generate impressive results in a UK trial to treat chronic leg ulcers.

All 20 patients treated with the company's dCELL Dermis saw a significant reduction in their wounds while nine were completely healed, it said.

The firm's dCELL Dermis is human skin that has been treated with its dCELLprocess - a patented technology that involves taking human or animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the risk of rejection.

The ongoing trial is being carried out in conjunction with the NHS Blood and Transplant division and is focused on people who have suffered with chronic ulcers for more than four years.

As well as the nine patients being healed, the surface area of all of the patient’s ulcers had halved in size, with volume also reduced significantly. The results were after six weeks.

The study also showed that the new skin could be applied in 30- 40 minutes without hospital admission in out-patient clinics and potentially GP surgeries.

Dr Ardeshir Bayat, the trial's principal investigator at the University Hospital of South Manchester said: "Chronic wounds of the lower leg are a clinical challenge and their on-going treatment costs the NHS in excess of £400m per annum. 

"Therefore a novel solution that can both reduce these costs and simultaneously offer a more effective treatment strategy has been long overdue."

Antony Odell, Tissue Regenix’s managing director, added: "People who suffer with chronic leg ulcers often do so for many years. 

"Traditional treatments using compression bandages are not effective in many cases and require regular hospital visits and the associated disruption to their daily lives."

He told Proactive Investors the firm was "very encouraged" by these results.

"It's another demonstration of the utility of the dCELL technology in another indication," he said.

The next step, he said, would be to carry out a larger clinical study, but also to begin to look at commercialising CELL Dermis.

Tissue is keen to see it launched outside the UK and has begun talks in the US about a clinical trial there, he said.

"We are quietly confident that we'll get some people to be interested enough to pick it up and want to do this clinical work."

Earlier, Odell told investors that the company expects to publish the results of a pre-clinical knee cartilage replacement trial before the end of the year, while a number of different products including the ligament and cardiac patch are due to enter preclinical studies.

Tissue Regenix has also been selected as one of only twenty UK healthcare companies to attend the Future Healthcare Mission to showcase the best in UK medical and healthcare science and technology to US investors and business partners, he said. 

“We believe Tissue Regenix is an excellent example of a British company with world-beating technology, which is based on research conducted in UK universities and pioneered through patient treatment in the NHS."

Tissue had net cash at the end of July of £26.1 mln. The company raised £25m through a share placing in December.

Losses in the half year rose to £1.87 mln from £1.34 mln reflecting the heavy product development currently underway, it said.

Shares rose today 12.22%, to stand at 12.50 pence.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use